|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
87,420,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Centessa Pharmaceuticals is a pharmaceutical company that develops and delivers life-altering and life-enhancing medicines to patients. Co.'s product pipeline includes: Lixivaptan, a vasopressin V2 receptor small molecule inhibitor; SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody for the treatment of cutaneous squamous cell carcinoma and for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin for the treatment of alpha-1-antitrypsin deficiency.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
10,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$46,284 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
55,427 |
55,427 |
114,211 |
368,796 |
Total Sell Value |
$642,534 |
$642,534 |
$973,119 |
$2,119,530 |
Total People Sold |
2 |
2 |
4 |
10 |
Total Sell Transactions |
2 |
2 |
6 |
35 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Saha Saurabh |
Chief Executive Officer |
|
2024-03-31 |
4 |
D |
$11.30 |
$409,772 |
D/D |
(36,263) |
868,187 |
|
- |
|
Bush Tia L |
Chief Technology & Quality Ofc |
|
2024-03-31 |
4 |
D |
$11.30 |
$72,535 |
D/D |
(6,419) |
170,064 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2024-03-31 |
4 |
D |
$11.30 |
$84,976 |
D/D |
(7,520) |
212,530 |
|
- |
|
Weinhoff Gregory M |
Chief Financial Officer |
|
2024-03-31 |
4 |
D |
$11.30 |
$132,685 |
D/D |
(11,742) |
265,111 |
|
- |
|
Chao David M |
Chief Administrative Officer |
|
2024-03-31 |
4 |
D |
$11.30 |
$117,351 |
D/D |
(10,385) |
272,986 |
|
- |
|
Anderson Karen M. |
Chief People Officer |
|
2024-03-25 |
4 |
AS |
$11.66 |
$607,960 |
D/D |
(51,160) |
71,525 |
|
- |
|
Anderson Karen M. |
Chief People Officer |
|
2024-03-25 |
4 |
OE |
$3.85 |
$177,252 |
D/D |
45,000 |
122,685 |
|
- |
|
Chao David M |
Chief Administrative Officer |
|
2024-02-01 |
4 |
D |
$8.19 |
$77,830 |
D/D |
(9,503) |
283,371 |
|
- |
|
Chao David M |
Chief Administrative Officer |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
292,874 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2024-02-01 |
4 |
D |
$8.19 |
$64,578 |
D/D |
(7,885) |
220,050 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
227,935 |
|
- |
|
Anderson Karen M. |
Chief People Officer |
|
2024-02-01 |
4 |
D |
$8.19 |
$59,500 |
D/D |
(7,265) |
77,685 |
|
- |
|
Anderson Karen M. |
Chief People Officer |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
31,250 |
84,950 |
|
- |
|
Rotman Harris |
SVP Regulatory Affairs |
|
2024-02-01 |
4 |
AS |
$8.10 |
$34,574 |
D/D |
(4,267) |
62,625 |
|
- |
|
Rotman Harris |
SVP Regulatory Affairs |
|
2024-02-01 |
4 |
D |
$8.19 |
$33,645 |
D/D |
(4,108) |
66,892 |
|
- |
|
Rotman Harris |
SVP Regulatory Affairs |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
71,000 |
|
- |
|
Bush Tia L |
Chief Quality Officer |
|
2024-02-01 |
4 |
D |
$8.19 |
$31,630 |
D/D |
(3,862) |
176,483 |
|
- |
|
Bush Tia L |
Chief Quality Officer |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
180,345 |
|
- |
|
Saha Saurabh |
Chief Executive Officer |
|
2024-02-01 |
4 |
D |
$8.19 |
$215,585 |
D/D |
(26,323) |
904,450 |
|
- |
|
Saha Saurabh |
Chief Executive Officer |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
144,200 |
930,773 |
|
- |
|
Weinhoff Gregory M |
Chief Financial Officer |
|
2024-02-01 |
4 |
D |
$8.19 |
$94,136 |
D/D |
(11,494) |
276,853 |
|
- |
|
Weinhoff Gregory M |
Chief Financial Officer |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
31,250 |
288,347 |
|
- |
|
Saha Saurabh |
Chief Executive Officer |
|
2023-12-31 |
4 |
D |
$7.96 |
$288,653 |
D/D |
(36,263) |
786,573 |
|
- |
|
Bush Tia L |
Chief Quality Officer |
|
2023-12-31 |
4 |
D |
$7.96 |
$51,095 |
D/D |
(6,419) |
137,845 |
|
- |
|
Grainger David J |
Chief Innovation Officer |
|
2023-12-31 |
4 |
D |
$7.96 |
$37,412 |
D/D |
(4,700) |
962,790 |
|
- |
|
147 Records found
|
|
Page 1 of 6 |
|
|